Vaxcyte, Inc.
A clinical-stage biotech making vaccines with its XpressCF cell-free protein synthesis platform, which builds conjugate shots without the immune-dampening carrier proteins that limit conventional pneumococcal vaccines. Its lead candidates, VAX-31 and VAX-24, aim at pneumococcal disease in adults and children, and its pipeline also covers strep and shigellosis. The company gained control of its cell-free extract manufacturing through an agreement with Sutro Biopharma.
Granted 564.5K · Sold 416.9K
Granted 305.5K · Sold 194.0K
Granted 219.1K · Sold 118.1K
Granted 53.4K · Sold 9.7K
Granted 105.5K · Sold 80.5K
Granted 71.2K · Sold 45.7K
Granted 35.9K · Sold 22.0K
Granted 1.6K
Granted 25.1K · Sold 18.2K
Granted 19.4K · Sold 12.5K
Granted 6.9K
Granted 12.5K
Granted 6.9K
Granted 5.3K
Granted 4.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Pickering GrantCHIEF EXECUTIVE OFFICER, Director · 174 transactions | +0.6% | 586.7K | 564.5K | — | 416.9K |
| Guggenhime AndrewPRESIDENT AND CFO · 87 transactions | — | 238.1K | 305.5K | — | 194.0K |
| Wassil JimCHIEF OPERATING OFFICER · 113 transactions | -6.2% | 158.5K | 219.1K | — | 118.1K |
| Dhaliwal Harpreet S.Chief Technical Ops Officer · 9 transactions | +248.4% | 76.0K | 53.4K | — | 9.7K |
| Eydelman MikhailSVP, GEN COUNSEL & CORP SEC · 88 transactions | +92.5% | 41.7Kas of Mar 2025 | 105.5K | — | 80.5K |
| Cowan ElviaSVP, Finance & CAO · 36 transactions | +341% | 32.0K | 71.2K | — | 45.7K |
| Lukatch HeathDirector · 14 transactions | +246.3% | 19.5K | 35.9K | — | 22.0K |
| Hirth PeterDirector · 1 transaction | +12.2% | 14.3Kas of Jun 2024 | 1.6K | — | — |
| Gilbert Halley EDirector · 5 transactions | +121.9% | 12.5K | 25.1K | — | 18.2K |
| Loxam TeriDirector · 17 transactions | +121.9% | 12.5K | 19.4K | — | 12.5K |
| Drapeau Anne SDirector · 3 transactions | +121.9% | 12.5K | 6.9K | — | — |
| Paya Carlos VDirector · 7 transactions | — | 12.5K | 12.5K | — | — |
| Lee JacksDirector · 3 transactions | — | 6.9K | 6.9K | — | — |
| Furey JohnDirector · 2 transactions | — | 5.3K | 5.3K | — | — |
| Brandicourt OlivierDirector · 3 transactions | — | 4.7K | 4.7K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -917.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.